Advertisement

Pneumo News

, Volume 11, Issue 1, pp 25–30 | Cite as

Chronische Erweiterungen der Bronchien

Bronchiektasen — lange versteckt, immer häufiger entdeckt

  • Isabell PinkEmail author
  • Sabine Dettmer
  • Tobias Welte
  • Jessica Rademacher
fortbildung
  • 9 Downloads

Bronchiektasen werden auch bei Patienten ohne Cystische Fibrose immer häufiger entdeckt. Das mag zu einem großen Teil an der verbesserten Diagnostik und der erhöhten Aufmerksamkeit für diese irreversiblen sackförmigen Ausweitungen der Bronchien liegen, in denen sich allzu gern Infektionen festsetzen. Leider bedeutet „Gefahr erkannt“ nicht immer auch „Gefahr gebannt“. Die Forschung steht hier noch ziemlich am Anfang.

Literatur

  1. 1.
    Chandrasekaran R, Mac Aogáin M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med 2018; 18Google Scholar
  2. 2.
    Lonni S, Chalmers JD, Goeminne PC et al. Etiology of Non—Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Ann Am Thorac Soc 2015; 12: 1764—1770CrossRefGoogle Scholar
  3. 3.
    Buscot M, Pottier H, Marquette C-H, Leroy S. Phenotyping Adults with Non-Cystic Fibrosis Bronchiectasis: A 10-Year Cohort Study in a French Regional University Hospital Center. Respiration 2016; 92: 1—8CrossRefGoogle Scholar
  4. 4.
    McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a Diverse US Population. Chest 2012; 142: 159—167CrossRefGoogle Scholar
  5. 5.
    Rademacher J, Ringshausen F. Non-CF-Bronchiektasen mit Fokus auf die allergische bronchopulmonale Aspergillose. Pneumologie 2013; 67: 40—49CrossRefGoogle Scholar
  6. 6.
    Ringshausen FC, de Roux A, Diel R et al. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J 2015; 46: 1805—1807CrossRefGoogle Scholar
  7. 7.
    Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, Simonet P, Miravitlles M. Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. Respir Med 2016; 121: 26—31.CrossRefGoogle Scholar
  8. 8.
    Quint JK, Millett ERC, Joshi M et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47: 186—193.CrossRefGoogle Scholar
  9. 9.
    Hill AT, Haworth CS, Aliberti S et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J 2017; 49: 1700051CrossRefGoogle Scholar
  10. 10.
    Chalmers JD, Goeminne P, Aliberti S et al. The Bronchiectasis Severity Index. An International Derivation and Validation Study. Am J Respir Crit Care Med 2014; 189: 576—585.CrossRefGoogle Scholar
  11. 11.
    Polverino E, Goeminne PC, McDonnell MJ et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629CrossRefGoogle Scholar
  12. 12.
    Nährlich L, Stuhrmann-Spangenberg M, Derichs N. Handlungsempfehlung nach der Leitlinie „Diagnose der Mukoviszidose“. Monatsschr Kinderheilkd 2014; 162: 723—724.CrossRefGoogle Scholar
  13. 13.
    Rademacher J, Buck A, Schwerk N et al. Nasal Nitric Oxide Measurement and a Modified PICADAR Score for the Screening of Primary Ciliary Dyskinesia in Adults with Bronchiectasis. Pneumologie 2017; 71: 543—548.CrossRefGoogle Scholar
  14. 14.
    Wilson R, Aksamit T, Aliberti S et al. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respir Med 2016; 117: 179—189.CrossRefGoogle Scholar
  15. 15.
    Murray MP, Govan JRW, Doherty CJ et al. A Randomized Controlled Trial of Nebulized Gentamicin in Non—Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491—499.Google Scholar
  16. 16.
    Scheinberg P. A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*. CHEST J 2005; 127: 1420.Google Scholar
  17. 17.
    Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. Am J Respir Crit Care Med 2014; 189: 975—982.CrossRefGoogle Scholar
  18. 18.
    Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas Aeruginosa. Ann Pharmacother 2005; 39: 39—44.CrossRefGoogle Scholar
  19. 19.
    Serisier DJ, Bilton D, De Soyza A et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812—817CrossRefGoogle Scholar
  20. 20.
    Aksamit T, Bandel T-J, Criollo M et al. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemp Clin Trials 2017; 58: 78—85.CrossRefGoogle Scholar
  21. 21.
    Wong C, Jayaram L, Karalus N et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. The Lancet 2012; 380: 660—667.CrossRefGoogle Scholar
  22. 22.
    Altenburg J, de Graaff CS, Stienstra Y et al. Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non—Cystic Fibrosis Bronchiectasis: The BAT Randomized Controlled Trial. JAMA 2013; 309: 1251.CrossRefGoogle Scholar
  23. 23.
    Serisier DJ, Martin ML, McGuckin MA et al. Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non—Cystic Fibrosis Bronchiectasis: The BLESS Randomized Controlled Trial. JAMA 2013; 309: 1260.CrossRefGoogle Scholar
  24. 24.
    EMBARC - Severity assessment. https://www.bronchiectasis.eu/severity-assessment (letzter Zugriff am 19.11.2018)

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Isabell Pink
    • 1
    Email author
  • Sabine Dettmer
    • 2
  • Tobias Welte
    • 1
  • Jessica Rademacher
    • 1
  1. 1.Klinik für PneumologieMedizinische Hochschule HannoverHannoverDeutschland
  2. 2.Institut für Diagnostische und Interventionelle RadiologieMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations